Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma

Affiliations

¹ Fox Chase Cancer Center, Philadelphia, PA, USA.
² Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: daniel.geynisman@fccc.edu.

Editorial

Benjamin Miron et al. Eur Urol. 2022 Oct.

. 2022 Oct;82(4):374-376.

doi: 10.1016/j.eururo.2022.05.023. Epub 2022 Jun 23.

¹ Fox Chase Cancer Center, Philadelphia, PA, USA.
² Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: daniel.geynisman@fccc.edu.

No abstract available

Comment on

Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
Siefker-Radtke AO, Cho DC, Diab A, Sznol M, Bilen MA, Balar AV, Grignani G, Puente E, Tang L, Chien D, Hoch U, Choudhury A, Yu D, Currie SL, Tagliaferri MA, Zalevsky J, Hurwitz ME, Tannir NM. Siefker-Radtke AO, et al. Eur Urol. 2022 Oct;82(4):365-373. doi: 10.1016/j.eururo.2022.05.002. Epub 2022 May 25. Eur Urol. 2022. PMID: 35643589 Clinical Trial.